DK36492D0 - Praeparat - Google Patents

Praeparat

Info

Publication number
DK36492D0
DK36492D0 DK92364A DK36492A DK36492D0 DK 36492 D0 DK36492 D0 DK 36492D0 DK 92364 A DK92364 A DK 92364A DK 36492 A DK36492 A DK 36492A DK 36492 D0 DK36492 D0 DK 36492D0
Authority
DK
Denmark
Prior art keywords
preparation
Prior art date
Application number
DK92364A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92364A priority Critical patent/DK36492D0/da
Publication of DK36492D0 publication Critical patent/DK36492D0/da
Priority to JP5516181A priority patent/JPH07504669A/ja
Priority to PCT/DK1993/000098 priority patent/WO1993018785A1/en
Priority to EP93907819A priority patent/EP0631504A1/en
Priority to AU38887/93A priority patent/AU3888793A/en
Priority to KR1019940703281A priority patent/KR950700754A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK92364A 1992-03-19 1992-03-19 Praeparat DK36492D0 (da)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat
JP5516181A JPH07504669A (ja) 1992-03-19 1993-03-18 新規薬剤
PCT/DK1993/000098 WO1993018785A1 (en) 1992-03-19 1993-03-18 Novel medicament
EP93907819A EP0631504A1 (en) 1992-03-19 1993-03-18 Novel medicament
AU38887/93A AU3888793A (en) 1992-03-19 1993-03-18 Novel medicament
KR1019940703281A KR950700754A (ko) 1992-03-19 1994-09-17 신규의 약물(novel medicament)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Publications (1)

Publication Number Publication Date
DK36492D0 true DK36492D0 (da) 1992-03-19

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Country Status (6)

Country Link
EP (1) EP0631504A1 (da)
JP (1) JPH07504669A (da)
KR (1) KR950700754A (da)
AU (1) AU3888793A (da)
DK (1) DK36492D0 (da)
WO (1) WO1993018785A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
CA2138161C (en) * 1992-06-15 2003-10-21 Glenn C. Andrews Glucagon-like peptide and insulinotropin derivatives
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1840134B1 (en) 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 derivatives
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
EP1932535A3 (en) 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
AU764371B2 (en) * 1998-08-28 2003-08-14 Eli Lilly And Company Method for administering insulinotropic peptides
ATE307603T1 (de) * 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
EP1263458B1 (en) 2000-03-08 2005-11-16 Novo Nordisk A/S Lowering serum cholesterol
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CA2545034C (en) 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
PL1817048T3 (pl) 2004-11-12 2014-07-31 Novo Nordisk As Stabilne preparaty peptydów insulinotropowych
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
MX2008007075A (es) * 2005-12-02 2008-11-12 Mdrna Inc Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
AU2009231439A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
KR20110137819A (ko) 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
JP2015500823A (ja) 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
EP4106724A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE69027022T2 (de) * 1989-02-17 1996-11-28 Liposome Co Inc Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung

Also Published As

Publication number Publication date
AU3888793A (en) 1993-10-21
JPH07504669A (ja) 1995-05-25
EP0631504A1 (en) 1995-01-04
WO1993018785A1 (en) 1993-09-30
KR950700754A (ko) 1995-02-20

Similar Documents

Publication Publication Date Title
DK36492D0 (da) Praeparat
DE59303358D1 (de) Quaterrylentetracarbonsäureimide
DE59306810D1 (de) Gutbettwalzenmühle
DE59302851D1 (de) Sportschuh
BR9305745A (pt) Quebra-luz
DE59301902D1 (de) Kassenlade
DE59305364D1 (de) Rotornut
DE59304139D1 (de) Polyanile
BR9301712A (pt) Aplainador
FIU920454U0 (fi) Raeddningsanordning
ATA227792A (de) Sportschuh
DE59309200D1 (de) Bisphosphinoalkane
DE59301762D1 (de) Chlorethylsulfonylbenzaldehyde
DK59092D0 (da) Praeparat
DE59206388D1 (de) Kabeleckkanal
BR9203234A (pt) Sofa-mesa
BR9200554A (pt) Lixoduto
BR9203235A (pt) Compactimer
BR9204065A (pt) Soprocóptero
BR9202793A (pt) Portimetro
BR9204074A (pt) Contramarco pre-moldano
BR9202723A (pt) Pipex
BR9202687A (pt) Minhoqueira
BR9202412A (pt) Hidrotermico
BR9204204A (pt) Gabanto

Legal Events

Date Code Title Description
ATS Application withdrawn